Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 276, Irina Babina, Concr

Getting predictive technologies to patients, with Concr

Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.

R&D

Concept of AI overview of patient in clinical trial

How AI simulation could help de-risk obesity and cardiometab...

AI life sciences models allow researchers to explore different patient populations, protocols, and development strategies before a study starts.

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Articles

Social pharma faces: Ed Bennett

Ed Bennett has journeyed from being a fire juggler to the director of web strategy at the University of Maryland Medical Centre. Here he describes this path and shares his thoughts on social media in the healthcare industry. In the latest in our social pharma faces series we’re stepping away from individuals in the pharma industry and onto a well known...

Articles

Direct to patient distribution – helping brands fight agains...

Hardik Singhvi looks at the benefits to pharmaceutical companies of ‘direct to patient’ product distribution, compared with the previous model, ‘direct to pharmacy’. Over the years, pharmaceutical companies have been selling their products through pre-wholesalers and regional wholesalers, because...

Articles

Pharma news highlights: July

This month’s news highlights, by Ed Silverman, include Pfizer and J&J’s cancellation of their Alzheimer’s drug studies and controversy following a vote by a California county in favour of drug makers disposing of expired prescription drugs. For the past several months, K-V Pharmaceutical regularly signalled that its ability to continue as a going concern is jeopardized...

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access